Sit Investment Associates Inc. Buys 8,038 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sit Investment Associates Inc. grew its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 22.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 44,390 shares of the biotechnology company's stock after purchasing an additional 8,038 shares during the quarter. Sit Investment Associates Inc.'s holdings in Sarepta Therapeutics were worth $5,397,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of SRPT. Manchester Capital Management LLC raised its holdings in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after buying an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its stake in shares of Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 156 shares in the last quarter. Sunbelt Securities Inc. raised its stake in shares of Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 232 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new stake in Sarepta Therapeutics in the 4th quarter worth approximately $36,000. Finally, Steward Partners Investment Advisory LLC boosted its position in Sarepta Therapeutics by 164.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 194 shares during the period. Institutional investors and hedge funds own 86.68% of the company's stock.

Remove Ads

Sarepta Therapeutics Price Performance

NASDAQ:SRPT traded up $0.84 on Friday, reaching $51.15. The stock had a trading volume of 1,137,085 shares, compared to its average volume of 1,375,392. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company has a market capitalization of $4.96 billion, a P/E ratio of 40.77 and a beta of 0.93. Sarepta Therapeutics, Inc. has a 1-year low of $48.01 and a 1-year high of $173.25. The stock has a fifty day moving average price of $89.37 and a 200-day moving average price of $110.71.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the business's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.70% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Royal Bank of Canada lowered shares of Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and dropped their price target for the company from $161.00 to $87.00 in a research report on Monday, March 31st. HC Wainwright upgraded shares of Sarepta Therapeutics from a "sell" rating to a "neutral" rating and set a $75.00 target price on the stock in a report on Wednesday, April 2nd. Morgan Stanley decreased their price target on shares of Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating for the company in a report on Friday. Scotiabank dropped their price objective on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating on the stock in a research note on Thursday, March 20th. Finally, Deutsche Bank Aktiengesellschaft cut their price objective on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a research report on Wednesday, March 19th. Six analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $161.83.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.